DataVXAdvanced SciencePaper
journal article·2024-08Open access

Leveraging Senescent Cancer Cell Membrane to Potentiate Cancer Immunotherapy Through Biomimetic Nanovaccine

Chao Yang, Yinglu Chen, Jie Liu, Wensheng Zhang, Yan He, Fangman Chen, Xiaochun Xie, Jie Tang, Shan Guan, Dan Shao, Zheng Wang, Liang Wang

Advanced Science· Volume 11· Issue 30
Publisher pageOpen full text
Source abstract

Abstract

Abstract Senescent cancer cells are endowed with high immunogenic potential that has been leveraged to elicit antitumor immunity and potentially complement anticancer therapies. However, the efficacy of live senescent cancer cell‐based vaccination is limited by interference from immunosuppressive senescence‐associated secretory phenotype and pro‐tumorigenic capacity of senescent cells. Here, a senescent cancer cell‐based nanovaccine with strong immunogenicity and favorable potential for immunotherapy is reported. The biomimetic nanovaccine integrating a senescent cancer cell membrane‐coated nanoadjuvant outperforms living senescent cancer cells in enhancing dendritic cells (DCs) internalization, improving lymph node targeting, and enhancing immune responses. In contrast to nanovaccines generated from immunogenic cell death‐induced tumor cells, senescent nanovaccines facilitate DC maturation, eliciting superior antitumor protection and improving therapeutic outcomes in melanoma‐challenged mice with fewer side effects when combined with αPD‐1. The study suggests a versatile biomanufacturing approach to maximize immunogenic potential and minimize adverse effects of senescent cancer cell‐based vaccination and advances the design of biomimetic nanovaccines for cancer immunotherapy.
Source: crossref · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Orthopedics Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases The Third Affiliated Hospital of Southern Medical University Guangzhou 510630 China

National Engineering Research Center for Tissue Restoration and Reconstruction South China University of Technology Guangzhou Guangdong 510006 China

School of Medicine South China University of Technology Guangzhou Guangdong 510006 China

Drug Delivery, Disposition and Dynamics Monash Institute of Pharmaceutical Sciences Monash University Parkville VIC 3052 Australia

National Engineering Research Center of Immunological Products Third Military Medical University Chongqing 400038 China

CAS Key Laboratory of Nano‐Bio Interface Suzhou Institute of Nano‐Tech and NanoBionics Chinese Academy of Sciences Suzhou 215123 China

Funding

National Natural Science Foundation of China · National Key Research and Development Program of China · Fundamental Research Funds for the Central Universities · Natural Science Foundation of Guangdong Province

References (46)

Show source-provided references
1. 10.1038/nm0303-26910.1038/nm0303-269 ↗
2. 10.1158/2159-8290.CD-20-120910.1158/2159-8290.CD-20-1209 ↗
3. 10.1016/j.apsb.2022.11.00110.1016/j.apsb.2022.11.001 ↗
4. 10.34133/2021/986287610.34133/2021/9862876 ↗
5. 10.34133/research.021110.34133/research.0211 ↗
6. 10.1016/j.actbio.2021.08.01410.1016/j.actbio.2021.08.014 ↗
7. 10.1038/s43018-022-00418-610.1038/s43018-022-00418-6 ↗
8. 10.1016/j.ymthe.2020.09.03810.1016/j.ymthe.2020.09.038 ↗
9. 10.1056/NEJMoa191733810.1056/NEJMoa1917338 ↗
10. 10.1126/sciadv.abb311610.1126/sciadv.abb3116 ↗
11. 10.1016/j.addr.2021.11392710.1016/j.addr.2021.113927 ↗
12. 10.1002/adma.20200809410.1002/adma.202008094 ↗
13. Zhu J. · Research · 2022 · 2022
14. 10.1016/j.cclet.2022.05.03210.1016/j.cclet.2022.05.032 ↗
15. 10.1002/adma.20170675910.1002/adma.201706759 ↗
16. 10.1002/advs.20190060510.1002/advs.201900605 ↗
17. 10.1002/advs.20210233010.1002/advs.202102330 ↗
18. 10.1021/nl500618u10.1021/nl500618u ↗
19. 10.1002/advs.20200202010.1002/advs.202002020 ↗
20. 10.1002/adma.20210379010.1002/adma.202103790 ↗
21. 10.1016/j.jconrel.2020.07.00810.1016/j.jconrel.2020.07.008 ↗
22. 10.1038/s41596-022-00713-710.1038/s41596-022-00713-7 ↗
23. 10.1002/adma.20231419710.1002/adma.202314197 ↗
24. 10.3390/pharmaceutics1110053410.3390/pharmaceutics11100534 ↗
25. 10.1016/j.addr.2021.11410710.1016/j.addr.2021.114107 ↗
26. 10.1021/acs.nanolett.1c0300410.1021/acs.nanolett.1c03004 ↗
27. 10.1016/j.jconrel.2023.05.04410.1016/j.jconrel.2023.05.044 ↗
28. 10.1038/s41581-022-00601-z10.1038/s41581-022-00601-z ↗
29. 10.1038/s41571-022-00668-410.1038/s41571-022-00668-4 ↗
30. 10.1038/s41568-022-00450-910.1038/s41568-022-00450-9 ↗
31. 10.1038/s41580-020-00314-w10.1038/s41580-020-00314-w ↗
32. 10.1038/s42255-021-00483-810.1038/s42255-021-00483-8 ↗
33. 10.1111/febs.1638110.1111/febs.16381 ↗
34. 10.1158/2159-8290.CD-22-052310.1158/2159-8290.CD-22-0523 ↗
35. 10.1126/scitranslmed.adg729110.1126/scitranslmed.adg7291 ↗
36. 10.1158/2159-8290.CD-22-052810.1158/2159-8290.CD-22-0528 ↗
37. 10.1016/j.ccell.2016.09.00310.1016/j.ccell.2016.09.003 ↗
38. 10.1002/1878-0261.1304210.1002/1878-0261.13042 ↗
39. 10.1038/s43018-022-00466-y10.1038/s43018-022-00466-y ↗
40. 10.1016/j.immuni.2023.08.01410.1016/j.immuni.2023.08.014 ↗
41. 10.1002/adma.20180119810.1002/adma.201801198 ↗
42. 10.1002/adma.20200438510.1002/adma.202004385 ↗
43. 10.1002/ange.20231794310.1002/ange.202317943 ↗
44. 10.1038/s41392-022-00942-y10.1038/s41392-022-00942-y ↗
45. 10.1002/smll.20220702910.1002/smll.202207029 ↗
46. 10.3389/fimmu.2019.0121610.3389/fimmu.2019.01216 ↗